I am founder and CEO of INanoBio, a startup developing advanced technologies at the interface of nanotechnology, biology and machine learning (ML) for future Healthcare 2.0. I believe that, as a scientific community, we can preempt 90% of all diseases. Disease preemption implies detection in pre-disease stages, followed by early intervention and cure, before full disease onset. However, we do not have the technology tools to achieve this today. To contribute, at INanoBio we are developing two product platforms to extract 100x more information from systems biology (genotype and phenotype) than currently possible. First is a novel semiconductor nanopore transistor device to sequence the DNA 100X faster than state of art, at 1/10th the cost. The second is a first-of-kind proteomic biosensor technology to study protein interactions at scale. INanoBio is based out of Menlo Park, California and Scottsdale, Arizona.
Founder & CEO, INanoBio